November 28, 2016 - By olga
Company insider, Frank Laukien, CEO – President of Bruker Corp acquired a total of 2,124 shares of the firm, based on an avg price of $22.9 per share. Today, he has rights to a total of 40.26 million shares or 25.25% of the company’s market cap. Dated 28/11/2016, this surprising transaction by Frank Laukien was unveiled in the a legal document filed together with the Security and Exchange Commission. It is freely available for review here.
Out of 11 analysts covering Bruker (NASDAQ:BRKR), 3 rate it a “Buy”, 2 “Sell”, while 6 “Hold”. This means 27% are positive. $28 is the highest target while $15 is the lowest. The $23.05 average target is 0.35% above today’s ($22.97) stock price. Bruker has been the topic of 21 analyst reports since August 20, 2015 according to StockzIntelligence Inc. On Thursday, August 20 the stock rating was maintained by BTIG Research with “Buy”. The stock of Bruker Corporation (NASDAQ:BRKR) has “Hold” rating given on Thursday, November 5 by Cantor Fitzgerald. The firm earned “Neutral” rating on Friday, July 22 by BTIG Research. The rating was downgraded by Leerink Swann to “Market Perform” on Tuesday, April 5. The rating was downgraded by Bank of America on Tuesday, April 5 to “Underperform”. Leerink Swann reinitiated the stock with “Market Perform” rating in Thursday, November 10 report. The firm has “Hold” rating given on Thursday, August 27 by Cantor Fitzgerald. BTIG Research maintained the stock with “Buy” rating in Thursday, September 17 report. The company was initiated on Thursday, January 7 by Deutsche Bank. The stock of Bruker Corporation (NASDAQ:BRKR) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, September 15.
Insitutional Activity: The institutional sentiment decreased to 0.7 in 2016 Q2. Its down 0.54, from 1.24 in 2016Q1. The ratio fall, as 24 funds sold all Bruker Corporation shares owned while 67 reduced positions. 25 funds bought stakes while 88 increased positions. They now own 105.58 million shares or 1.06% less from 106.71 million shares in 2016Q1.
Meeder Asset owns 20,337 shares or 0.04% of their US portfolio. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Corp, a Alberta – Canada-based fund reported 12,000 shares. Babson Mngmt Limited Company holds 48,200 shares or 0.03% of its portfolio. Citadel Advsrs Ltd Llc has invested 0.01% of its portfolio in Bruker Corporation (NASDAQ:BRKR). Great Lakes Advisors Lc holds 0.14% or 224,621 shares in its portfolio. Utah Retirement System last reported 18,989 shares in the company. The New York-based D E Shaw & Inc has invested 0.06% in Bruker Corporation (NASDAQ:BRKR). Paloma Prtn Comm holds 57,860 shares or 0.01% of its portfolio. Blackrock Inv Mgmt Ltd Liability, a New Jersey-based fund reported 40,246 shares. Smith Asset Mgmt Group Incorporated Lp holds 392,630 shares or 0.27% of its portfolio. Gsa Prtn Llp has invested 0.19% of its portfolio in Bruker Corporation (NASDAQ:BRKR). Verition Fund Mngmt Ltd Liability Com has 0.03% invested in the company for 10,048 shares. Systematic Fincl Lp owns 75,480 shares or 0.02% of their US portfolio. Geode Capital Management Lc accumulated 1.22M shares or 0.02% of the stock. The New York-based Teachers Advsrs has invested 0% in Bruker Corporation (NASDAQ:BRKR).
Insider Transactions: Since June 6, 2016, the stock had 3 insider buys, and 1 insider sale for $50.88 million net activity. On Friday, August 5 the insider LAUKIEN FRANK H bought $99,752. 2.00M shares were sold by LAUKIEN JOERG C, worth $51.30 million on Monday, June 6. On Wednesday, August 10 PACKER RICHARD A bought $219,692 worth of the stock or 10,000 shares.
About 8,699 shares traded hands. Bruker Corporation (NASDAQ:BRKR) has declined 19.58% since April 25, 2016 and is downtrending. It has underperformed by 25.59% the S&P500.
Bruker Corporation is a designer and maker of scientific instruments, and analytical and diagnostic solutions. The company has a market cap of $3.68 billion. The Company’s operating divisions include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment. It has a 25.92 P/E ratio. The Bruker BioSpin Group segment designs, makes and distributes enabling life science tools.
According to Zacks Investment Research, “As of February 26, 2008, the renamed BRUKER CORPORATION has become the parent company of the entire Bruker group of companies. After the closing of the acquisition of the Bruker BioSpin Group, Bruker Corporation now operates in two segments, the life science and analytical (LSA) systems segment, and the international advanced superconductor (IAS) segment.”
Analysts await Bruker Corporation (NASDAQ:BRKR) to report earnings on February, 8. They expect $0.37 earnings per share, down 2.63% or $0.01 from last year’s $0.38 per share. BRKR’s profit will be $59.22M for 15.49 P/E if the $0.37 EPS becomes a reality. After $0.32 actual earnings per share reported by Bruker Corporation for the previous quarter, Wall Street now forecasts 15.63% EPS growth.
More notable recent Bruker Corporation (NASDAQ:BRKR) news were published by: Prnewswire.com which released: “Bruker and Oxford Instruments Announce Acquisition of Oxford Instruments ..” on November 17, 2016, also Prnewswire.com with their article: “Bruker Announces Quarterly Dividend” published on November 14, 2016, Fool.com published: “Why Bruker Corp. Is Crashing 12% Today” on August 03, 2016. More interesting news about Bruker Corporation (NASDAQ:BRKR) were released by: Prnewswire.com and their article: “Bruker Accelerates Extreme Resolution Isotope Fine Structure (IFS) Mass ..” published on August 22, 2016 as well as Prnewswire.com‘s news article titled: “Bruker Reports Third Quarter 2016 Financial Results” with publication date: November 02, 2016.
Bruker Corporation, incorporated on February 4, 2000, is a designer and maker of scientific instruments, and analytical and diagnostic solutions. The Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s operating divisions include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment. The Bruker BioSpin Group segment designs, makes and distributes enabling life science tools based on magnetic resonance and preclinical imaging technologies. The Bruker CALID segment designs, makes and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as chemical, biological, radiological, nuclear and explosive (CBRNE) detection products. The Bruker Nano segment designs, makes and distributes spectroscopy and microscopy instruments for the understanding of composition and structure in material science and life science samples. The BEST segment develops and makes superconducting and non-superconducting materials and devices.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.